Cwm LLC Grows Position in DexCom, Inc. (NASDAQ:DXCM)

Cwm LLC grew its stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 2.4% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 166,144 shares of the medical device company's stock after purchasing an additional 3,897 shares during the period. Cwm LLC's holdings in DexCom were worth $11,346,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Stephens Investment Management Group LLC raised its stake in shares of DexCom by 19.5% during the 1st quarter. Stephens Investment Management Group LLC now owns 841,084 shares of the medical device company's stock worth $57,438,000 after buying an additional 137,165 shares during the period. Xponance Inc. raised its stake in shares of DexCom by 1.1% during the 1st quarter. Xponance Inc. now owns 90,222 shares of the medical device company's stock worth $6,161,000 after buying an additional 1,023 shares during the period. Cerity Partners LLC raised its stake in shares of DexCom by 4.1% during the 1st quarter. Cerity Partners LLC now owns 69,601 shares of the medical device company's stock worth $4,753,000 after buying an additional 2,711 shares during the period. Alps Advisors Inc. raised its stake in shares of DexCom by 43.8% during the 1st quarter. Alps Advisors Inc. now owns 17,137 shares of the medical device company's stock worth $1,170,000 after buying an additional 5,219 shares during the period. Finally, Allworth Financial LP raised its stake in shares of DexCom by 163.3% during the 1st quarter. Allworth Financial LP now owns 2,846 shares of the medical device company's stock worth $201,000 after buying an additional 1,765 shares during the period. Hedge funds and other institutional investors own 97.75% of the company's stock.

DexCom Stock Performance

Shares of DexCom stock opened at $85.33 on Tuesday. The business has a 50-day moving average of $84.45 and a 200 day moving average of $80.03. DexCom, Inc. has a 12 month low of $57.52 and a 12 month high of $117.19. The stock has a market capitalization of $33.46 billion, a price-to-earnings ratio of 63.68, a price-to-earnings-growth ratio of 1.78 and a beta of 1.44. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.50 and a quick ratio of 1.32.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). DexCom had a net margin of 12.90% and a return on equity of 30.05%. The firm had revenue of $1.04 billion for the quarter, compared to analysts' expectations of $1.02 billion. During the same quarter last year, the business earned $0.32 earnings per share. The business's revenue was up 12.5% compared to the same quarter last year. As a group, sell-side analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts recently commented on DXCM shares. Piper Sandler reduced their price objective on DexCom from $100.00 to $90.00 and set an "overweight" rating for the company in a research note on Friday, May 2nd. The Goldman Sachs Group started coverage on DexCom in a research note on Friday, May 30th. They issued a "buy" rating and a $104.00 price objective for the company. Citigroup reissued a "buy" rating and issued a $102.00 price objective (up from $82.00) on shares of DexCom in a research note on Thursday, May 22nd. Barclays increased their price objective on DexCom from $90.00 to $93.00 and gave the company an "equal weight" rating in a research note on Monday, May 5th. Finally, Cfra Research raised DexCom to a "hold" rating in a research note on Friday, March 21st. Five investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, DexCom currently has an average rating of "Moderate Buy" and an average target price of $98.50.

Insider Transactions at DexCom

In other news, EVP Michael Jon Brown sold 10,000 shares of DexCom stock in a transaction dated Friday, May 23rd. The stock was sold at an average price of $84.28, for a total value of $842,800.00. Following the completion of the transaction, the executive vice president owned 95,602 shares in the company, valued at approximately $8,057,336.56. This trade represents a 9.47% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Nicholas Augustinos sold 3,672 shares of DexCom stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $82.80, for a total value of $304,041.60. Following the completion of the transaction, the director owned 33,411 shares of the company's stock, valued at $2,766,430.80. The trade was a 9.90% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 27,190 shares of company stock valued at $2,281,732. Insiders own 0.32% of the company's stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.